Please assess the completion status of the following clinical trial:

Trial Title: Toujeo Versus NPH Self-titration Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetic suboptimally controlled on their previous antidiabetic treatment~  * 18 ≤ age ≤ 75~ * Stable dose of oral antidiabetic treatment for \> 8 weeks~ * The number of OADs that the patients used should be 3 or less~ * HbA1c level \> 7.0% and \< 10%~ * Fasting plasma glucose \> 8mmol/L and \<15mmol~ * BMI \< 40 kg/m2~ * Patient who is capable and willing to perform regular SMBG~ * Patient who is capable and willing for insulin injection~ * Confirmed written consent~ * Insulin naïve~Exclusion Criteria:~* Participation in a clinical trial with any investigational drug used with curative intent and within 30 days prior to study entry~* Patient known to have hypoglycaemia unawareness or recurrent major hypoglycaemia~* Any product containing prandial insulin~* Concomitant medication known to interface with glucose metabolism (such as systematic steroids)~* Change in dose of non-insulin anti-diabetic treatment or initiation of new anti-diabetic medications in the last 8 weeks prior to screening~* Patients treated with steroid or nonsteroidal anti-inflammatory drugs~* Patient who had experienced an acute concurrent illness during the 3-month period before the investigation~* Patient with hepatic disease and end-stage renal disease~* Patients unable to comply with follow-up visits~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Insulin glargine 300U/ml
- Control (Type: ACTIVE_COMPARATOR): Neutral Protamine Hagedorn insulin

Based on this trial design, predict the completion outcome and termination type (if applicable).